title: Psychotropic medication in the French child and adolescent population: prevalence estimation from health insurance data and national self-report survey data.
abstract: BACKGROUND
  The aim of this work is to estimate the French frequencies of dispensed psychotropic prescriptions in children and adolescents. Prevalence estimations of dispensed prescriptions are compared to the frequencies of use of psychotropic reported by 17 year-old adolescents.
  
  
  METHODS
  Prescription data is derived from national health insurance databases. Frequencies of dispensed prescriptions are extrapolated to estimate a range for the 2004 national rates. Self-report data is derived from the 2003 and 2005 ESCAPAD study, an epidemiological study based on a questionnaire focused on health and drug consumption.
  
  
  RESULTS
  The prevalence estimation shows that the prevalence of prescription of a psychotropic medication to young persons between 3 and 18 years is about 2.2%.In 2005, the self-report study (ESCAPAD) shows that 14.9% of 17 year-old adolescents took medication for "nerves" or "to sleep" during the previous 12 months. The same study in 2003 also shows that 62.3% of adolescents aged 17 and 18 reporting psychotropic use, took the medication for anxiety and 56.8% to sleep. Only 49.7% of these medications are suggested by a doctor.
  
  
  CONCLUSIONS
  This study underlines a similar range of prevalence of psychotropic prescriptions in France to that observed in other European countries. Nevertheless, the proportion of antipsychotics and benzodiazepines seems to be higher, whereas the proportion of methylphenidate is lower.Secondly, a disparity between the prevalence of dispensed prescriptions and the self-report of actual use of psychotropics has been highlighted by the ESCAPAD study which shows that these treatments are widely used as "self-medication".
authors.affiliation: Inserm U669, PSIGIAM, Paris, France. dracquaviva@aol.com
authors.forename: Eric
authors.initials: E
authors.lastname: Acquaviva
authors.forename: Stéphane
authors.initials: S
authors.lastname: Legleye
authors.forename: Guy R
authors.initials: GR
authors.lastname: Auleley
authors.forename: Jean
authors.initials: J
authors.lastname: Deligne
authors.forename: Didier
authors.initials: D
authors.lastname: Carel
authors.forename: Bruno
authors.initials: B
authors.lastname: Falissard B
mesh_terms: D000293:Adolescent; D000328:Adult; D017677:Age Distribution; D000367:Age Factors; D001569:Benzodiazepines / Q000627:therapeutic use; D002648:Child; D011307:Drug Prescriptions / Q000706:statistics & numerical data; D004363:Drug Utilization / Q000706:statistics & numerical data; D005060:Europe / Q000453:epidemiology; D005260:Female; D005602:France / Q000453:epidemiology; D006801:Humans; D008297:Male; D008774:Methylphenidate / Q000627:therapeutic use; D008875:Middle Aged; D009313:National Health Programs / Q000706:statistics & numerical data; D015995:Prevalence; D011619:Psychotropic Drugs / Q000627:therapeutic use*; D012651:Self Medication / Q000706:statistics & numerical data; D011795:Surveys and Questionnaires
chemical_list: D011619:Psychotropic Drugs; D001569:Benzodiazepines; D008774:Methylphenidate